Homocysteine, Ischemic Stroke, and Coronary Heart Disease in Hypertensive Patients: A Population-Based, Prospective Cohort Study

Stroke

Volumn 46, Issue 7, 2015, Pages 1777-1786

  Han, Liyuan ^a   Wu, Qunhong ^b   Wang, Changyi ^c   Hao, Yanhua ^b   Zhao, Jinshun ^a   Zhang, Lina ^a   Fan, Rui ^a   Liu, Yanfen ^a   Li, Runhua ^a   Chen, Zhongwei ^c   Zhang, Tao ^c   Chen, Sihan ^c   Ma, Jianping ^c   Liu, Shengyuan ^c   Peng, Xiaolin ^c   Duan, Shiwei ^a  

^a NINGBO UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Shenzhen Nanshan Center for Chronic Disease Control   (China)

Author keywords

coronary heart disease; homocysteine; hypertension; ischemia; stroke

Indexed keywords

CREATININE; FOLIC ACID; GLUCOSE; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; AMINO ACID BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIAC PATIENT; CHINA; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DIETARY INTAKE; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; FRUIT; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALT INTAKE; SILENT MYOCARDIAL ISCHEMIA; SMOKING; STROKE PATIENT; SUBARACHNOID HEMORRHAGE; SUDDEN DEATH; VEGETABLE; VITAMIN SUPPLEMENTATION; BLOOD; CORONARY DISEASE; HEALTH SURVEY; RISK FACTOR; STROKE;

ADULT; AGED; BRAIN ISCHEMIA; CHINA; COHORT STUDIES; CORONARY DISEASE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84941031223     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.009111     Document Type: Article

References (49)

1. Sun H, Zou X, Liu L. Epidemiological factors of stroke: a survey of the current status in china. J Stroke. 2013;15:109-114. doi: 10.5853/jos.2013.15.2.109.
2. Wy S, Jy L. Stroke subtype classification: a comparative study of ASCO and modified TOAST. J Neurol Sci. 2012;314:66-70.
3. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381:1987-2015. doi: 10.1016/S0140-6736(13)61097-1.
4. Moran A, Zhao D, Gu D, Coxson P, Chen CS, Cheng J, et al. The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China. BMC Public Health. 2008;8:394. doi: 10.1186/1471-2458-8-394.
5. Jacques PF, Kalmbach R, Bagley PJ, Russo GT, Rogers G, Wilson PW, et al. The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr. 2002;132:283-288.
6. Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet. 2011;378:584-594. doi: 10.1016/S0140-6736(11)60872-6.
7. Wang CY, Chen ZW, Zhang T, Liu J, Chen SH, Liu SY, et al. Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients. Eur J Intern Med. 2014;25:538-544. doi:10.1016/j.ejim.2014.04.011.
8. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370:591-603. doi: 10.1016/S0140-6736(07)61299-9.
9. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation. 2000;101:329-335.
10. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536. doi: 10.1093/eurheartj/ehm236.
11. Joint Committee for developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults. [Chinese guidelines on prevention and treatment of dyslipidemia in adults]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35:390-419.
12. American Diabetes Association.Executive summary: standards of medical care in diabetes-2009. Diabetes Care. 2009;32(suppl 1):S6-S12.
13. Kriska AM, Saremi A, Hanson RL, Bennett PH, Kobes S, Williams DE, et al. Physical activity, obesity, and the incidence of type 2 diabetes in a high-risk population. Am J Epidemiol. 2003;158:669-675.
14. Halanych JH, Safford MM, Kertesz SG, Pletcher MJ, Kim YI, Person SD, et al. Alcohol consumption in young adults and incident hypertension: 20-year follow-up from the Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol. 2010;171:532-539. doi: 10.1093/aje/kwp417.
15. Langley J, Kypri K, Cryer C, Davie G. Assessing the validity of potential alcohol-related non-fatal injury indicators. Addiction. 2008;103:397-404. doi: 10.1111/j.1360-0443.2007.02089.x.
16. Romera I, Delgado-Cohen H, Perez T, Caballero L, Gilaberte I. Factor analysis of the Zung self-rating depression scale in a large sample of patients with major depressive disorder in primary care. BMC Psychiatry. 2008;8:4. doi: 10.1186/1471-244X-8-4.
17. Barnard J, Meng XL. Applications of multiple imputation in medical studies: from AIDS to NHANES. Stat Methods Med Res. 1999;8:17-36.
18. Christopher R, Nagaraja D, Shankar SK. Homocysteine and cerebral stroke in developing countries. Curr Med Chem. 2007;14:2393-2401.
19. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11:116-128.
20. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775-1781.
21. Hung CY, Wang KY, Wu TJ, Hsieh YC, Huang JL, Lohel-W, et al. Resistant hypertension, patient characteristics, and risk of stroke. PLoS One. 2014;9:e104362. doi: 10.1371/journal.pone.0104362.
22. Gorgui J, Gorshkov M, Khan N, Daskalopoulou SS. Hypertension as a risk factor for ischemic stroke in women. Can J Cardiol. 2014;30:774-782. doi: 10.1016/j.cjca.2014.01.007.
23. Sundström J, Sullivan L, D'Agostino RB, Jacques PF, Selhub J, Rosenberg IH, et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. Hypertension. 2003;42:1100-1105. doi: 10.1161/01.HYP.0000101690.58391.13.
24. Bonassi MR, Chada BE, Eduardo FC, Marcelo LE, De Lima G R. Effects of estrogen and estrogen-progestogen therapy on homocysteine levels andtheir correlation with carotid vascular resistance. Gynecol Endocrinol. 2007;23:619-624.
25. Gaikwad NW. Mass spectrometry evidence for formation of estrogen-homocysteine conjugates: estrogens can regulate homocysteine levels. Free Radic Biol Med. 2013;65:1447-1454. doi: 10.1016/j. freeradbiomed.2013.07.041.
26. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. Homocysteine and essential hypertension. J Clin Pharmacol. 2003;43:1299-1306. doi:10.1177/0091270003258190.
27. van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and blood pressure. Curr Hypertens Rep. 2003;5:26-31.
28. Martí-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2013;1:CD006612. doi:10.1002/14651858.CD006612.pub3.
29. Joseph J, Loscalzo J. Methoxistasis: integrating the roles of homocysteine and folic acid in cardiovascular pathobiology. Nutrients. 2013;5:3235-3256. doi: 10.3390/nu5083235.
30. Clarke R, Bennett DA, Parish S, Verhoef P, Dötsch-Klerk M, Lathrop M, et al; MTHFR Studies Collaborative Group. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med. 2012;9:e1001177. doi: 10.1371/journal.pmed.1001177.
31. Gopinath B, Flood VM, Rochtchina E, Thiagalingam A, Mitchell P. Serum homocysteine and folate but not vitamin B12 are predictors of CHD mortality in older adults. Eur J Prev Cardiol. 2012;19:1420-1429. doi: 10.1177/1741826711424568.
32. Mark SD, Wang W, Fraumeni JF Jr, Li JY, Taylor PR, Wang GQ, et al. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol. 1996;143:658-664.
33. Hu DY, Xu XP. [Prevention of stroke relies on valid control "H" type hypertension]. Zhonghua Nei Ke Za Zhi. 2008;47:976-977.
34. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C-T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005;331:1053. doi: 10.1136/bmj.38611.658947.55.
35. Poli D, Antonucci E, Cecchi E, Marcucci R, Liotta AA, Cellai AP, et al. Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke. 2005;36:2159-2163. doi: 10.1161/01.STR.0000183620.06179.7b.
36. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol. 2007;6:830-838. doi: 10.1016/S1474-4422(07)70219-3.
37. Spence D. Mechanisms of thrombogenesis in atrial fibrillation. Lancet. 2009;373:1006; author reply 1006-1006; author reply 1007. doi:10.1016/S0140-6736(09)60604-8.
38. Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol. 1999;19:405-410.
39. Spence JD. B vitamin therapy for homocysteine: renal function and vitamin B12 determine cardiovascular outcomes. Clin Chem Lab Med. 2013;51:633-637. doi: 10.1515/cclm-2012-0465.
40. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA. 2010;303:1603-1609. doi:10.1001/jama.2010.490.
41. Spence JD. Nutrition and stroke prevention. Stroke. 2006;37:2430-2435. doi: 10.1161/01.STR.0000236633.40160.ee.
42. Koyama K, Yoshida A, Takeda A, Morozumi K, Fujinami T, Tanaka N. Abnormal cyanide metabolism in uraemic patients. Nephrol Dial Transplant. 1997;12:1622-1628.
43. Alsagaff MY, Thaha M, Aminuddin M, Yogiarto RM, Yogiantoro M, Tomino Y. Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease. J Int Med Res. 2012;40:340-349.
44. Koyama K, Ito A, Yamamoto J, Nishio T, Kajikuri J, Dohi Y, et al. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis. Am J Kidney Dis. 2010;55:1069-1078. doi: 10.1053/j.ajkd.2009.12.035.
45. Matteo CM, K SR, Scicchitano P, Cortese F, Salerno C, Berchialla P, et al. Dolichocarotids: echo-color Doppler evaluation and clinical role. J Atheroscler Thromb. 2014;21:56-63.
46. Ciccone MM, Scicchitano P, Palumbo V, Cortese F, Valecce R, Dentamaro I, et al. Dolichocarotids and dilated cardiomyopathy: is there a relationship? Int J Cardiol. 2012;158:123-125. doi: 10.1016/j. ijcard.2012.04.052.
47. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol. 2008;126:302-312. doi: 10.1016/j.ijcard.2007.08.077.
48. Scicchitano P, Cortese F, Ricci G, Carbonara S, Moncelli M, Iacoviello M, et al. Ivabradine, coronary artery disease, and heart failure: beyond rhythm control. Drug Des Devel Ther. 2014;8:689-700. doi: 10.2147/DDDT.S60591.
49. Scicchitano P, Carbonara S, Ricci G, Mandurino C, Locorotondo M, Bulzis G, et al. HCN channels and heart rate. Molecules. 2012;17:4225-4235. doi: 10.3390/molecules17044225.